Cereno Scientific to present preclinical data for candidate drug CS585 at EHA2023 Hybrid Congress – the premier medical congress for hematology

Cereno Scientific (XSAT: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that an abstract on preclinical drug candidate CS585 has been accepted as an oral presentation by the Scientific Program Committee at the European Hematology Association (EHA) 2023 Hybrid Congress in Frankfurt, Germany, on June 8-11. The abstract “Sustained inhibition of platelet activity and thrombosis via IV and oral administration of CS585” will be presented by Dr. Michael Holinstat, lead of Cereno’s preclinical development programs at University of Michigan and Director of Translational Research at Cereno.

The abstract titled “Sustained inhibition of platelet activity and thrombosis via IV and oral administration of CS585”, was authored by Sylviane Lambert and Andrew Rickenberg at Pharmacology, University of Michigan Medical School; Björn Dahlöf and Niklas Bergh at Cereno Scientific and Institute of Medicine, University of Gothenburg; Michael Holinstat at Pharmacology, University of Michigan Medical School. The abstract has been selected to be presented as an oral presentation by Dr. Michael Holinstat.

The EHA2023 Hybrid Congress is organized by the European Hematology Association (EHA). The congress specializes in hematology and its subspecialties, particularly, cutting-edge evidence-based approaches to diagnosis and treatment, highly anticipated clinical and translational research data, and the newest developments in innovative techniques, diagnostic tools, and risk-assessment strategies. The in-person congress is held in Frankfurt, Germany June 8 - 11, 2023; and the virtual days on June 14 - 15, 2023.

Details on the oral presentation at EHA2023:

Title: SUSTAINED INHIBITION OF PLATELET ACTIVITY AND THROMBOSIS VIA IV AND ORAL ADMINISTRATION OF CS585
Session Title: Novel diagnostic, therapeutic and predictive insights in thrombotic disorders
Session date and time:  Friday, 9 June, 15:45 - 16:00 CEST
Session room: Hall Goldman
Final Abstract Code: S309
Presenting Author: Dr. Michael Holinstat

For further information, please contact:

Jonas Fogelberg, Interim CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.